Abstract
The term "iatrogenic comorbidity" refers to unfavorable modifications in the course of an illness, with regard to its characteristics and responsiveness, which may be related to previous treatments. Some iatrogenic adverse events arising from either pharmacotherapy or psychotherapy cannot be subsumed under the traditional rubric of adverse effects and require careful evaluation. Children and adolescents are generally more likely to experience adverse health consequences after drug treatment. The use of antidepressant drugs in this age group may cause potential long-term detrimental effects, such as mood elevation that does not subside when drugs are discontinued and may predispose to the development of a bipolar disorder. The concept of iatrogenic comorbidity in children and adolescents has heuristic value in weighing potential benefits and risks associated particularly with psychotropic treatments.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 769-774 |
| Number of pages | 6 |
| Journal | CNS Drugs |
| Volume | 28 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Iatrogenic comorbidity in childhood and adolescence: New insights from the use of antidepressant drugs'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver